Acumen Pharmaceuticals said that an experimental Alzheimer’s drug developed by the company has passed an initial safety test, and will move to larger trials. The drug targets a new form of the toxic beta-amyloid protein in the brain.
The company said the drug, ACI-193, was well received in its first trial in patients.
The company presented the results of the study, which was conducted on a random sample of 62 patients, who had early symptoms of Alzheimer’s disease, at the International Conference of the Alzheimer’s Association in Amsterdam.
The study included a comparison between a group of participants who were given the drug with another group that was given a placebo.
The new drug, developed by the company, targets and binds to oligomers of beta-amyloid, a toxic, soluble version of the amyloid protein that forms brain plaques associated with the disease, Dr. Eric Simmers, Acumen’s chief medical officer, said in an interview.
In the Acumen trial, the company said those who get higher doses of the new drug had lower rates of amyloid plaques after a period of between six and 12 weeks, suggesting that the drug might be given to patients intravenously once a month.
2023-07-16 13:29:22
#Alzheimers #drug #passes #safety #test
